TCRX Stock — TScan Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.31

Market cap

$19.8M

Cash

$100.2M

Enterprise value

-$59.3M

Balance sheet

Cash	$100.2M
Debt	$21.1M
Net cash	$79.1M
Enterprise value	-$59.3M
Basic shares	129.9M shares
Fully diluted shares	153.3M shares
Fully diluted market cap	$47.5M
Cash per share	$0.77

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TCRX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 10 - Mar 24	TSC-204-A0201	Phase 1	Head and Neck Cancer; Cervical Cancer; Non-small Cell Carcinoma	—
Jul 13 - Aug 24	TSC-101	Phase 3	AML; MDS	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

TSC-101

Phase 3 · Active Modality: TCR-engineered T cell (TCR-T) therapy

Target HA-2 (in patients with HLA type A*02:01)

Indications

Acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT) (Phase 3)
Myelodysplastic syndromes (MDS) undergoing allogeneic HCT (Phase 3)

Status note Phase 3 registrational trial ALLOHA-2 in AML/MDS undergoing allogeneic HCT; first patient dosed Jul 2026. Phase 1 ALLOHA trial ongoing.

TSC-102-A01

Stage not disclosed · Active Modality: TCR-engineered T cell (TCR-T) therapy (allogeneic, donor-derived)

Target CD45 (HLA-A*01:01)

Indications

Hematologic malignancies undergoing HCT (Stage not disclosed)

Status note Donor-derived TCR-T candidate targeting CD45 in patients with HLA type A*01:01 undergoing HCT.

TSC-102-A03

Stage not disclosed · Active Modality: TCR-engineered T cell (TCR-T) therapy (allogeneic, donor-derived)

Target CD45 (HLA-A*03:01)

Indications

Hematologic malignancies undergoing HCT (Stage not disclosed)

Status note Donor-derived TCR-T candidate targeting CD45 in patients with HLA type A*03:01 undergoing HCT.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TSC-101
Lead indication	AML
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07702578	Phase 3	Recruiting	Sponsor	TCRX	—	AML; MDS	—
NCT05973487	Phase 1	Active, not recruiting	Sponsor	TCRX	—	Head and Neck Cancer; Cervical Cancer; Non-small Cell Carcinoma	—
NCT05473910	Phase 1	Recruiting	Sponsor	TCRX	—	AML; MDS	—
NCT06976736	Not disclosed	Recruiting	Sponsor	TCRX	—	AML; ALL; MDS	—
NCT05812027	Not disclosed	Active, not recruiting	Sponsor	TCRX	—	Head and Neck Cancer; Cervical Cancer; Non Small Cell Lung Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for TScan Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	2,784,792	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TCRX — TScan Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders